Everything below concerns lyophilised powder. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-03-22. Where a claim depends on a specific study, the study is described rather than over-claimed.
Several names circulate for the same molecule, including epitalon, epithalone, epithalamin tetrapeptide, and the sequence code AEDG. A CAS registry number, 307297-39-8, is commonly cited for it, though catalogue entries should be checked against supplier documentation because mislabelled records occur. In its usual form the peptide carries free amino and carboxyl termini and is neither glycosylated nor lipidated. Researchers distinguish the defined tetrapeptide from epithalamin itself, a crude pineal preparation containing many peptides that is not chemically characterised.
Material supplied for laboratory use is normally a lyophilised white to off-white powder that dissolves readily in water and in isotonic saline. Lyophilised cakes are hygroscopic and should be equilibrated to room temperature before opening to limit condensation on the solid. Solutions are typically prepared at milligram-per-millilitre concentrations and divided into single-use aliquots, because repeated freeze–thaw cycles degrade short peptides. Aqueous solutions are far less stable than the dry powder, and identity is usually verified by mass spectrometry alongside purity estimation from reversed-phase high-performance liquid chromatography.
Epitalon is a synthetic linear tetrapeptide with the sequence alanine–glutamate–aspartate–glycine, abbreviated AEDG. Its molecular formula is C14H22N4O9 and the calculated mass is approximately 390.35 g/mol. The compound is made by solid-phase peptide synthesis rather than extracted from tissue, although early work described it as a short fragment of a peptide fraction obtained from bovine pineal extract. In the research literature the spelling epitalon and the variant epithalone both appear, while AEDG is the standard code used in peptide nomenclature.
Published work on this compound consists mainly of in vitro experiments, animal studies, and small clinical investigations, a substantial share of which appeared in Russian-language journals. Sample sizes are generally small, control conditions differ between studies, and several endpoints rely on markers whose clinical meaning is itself debated. Reviews of the longevity field treat the peptide as an early example of telomerase-directed research rather than an established intervention. Regulatory treatment varies by country: some jurisdictions place it under prescription controls, others treat it as a laboratory material, and importation may be restricted regardless of local status.
Epitalon is a synthetic tetrapeptide whose sequence is alanine–glutamate–aspartate–glycine, commonly abbreviated AEDG. It was developed in Russia during the 1980s and 1990s by investigators associated with the St. Petersburg Institute of Bioregulation and Gerontology, who studied short peptides as regulators of gene expression and tissue function. The alternative spelling epithalon appears interchangeably in the literature, and the two names refer to the same molecule. Outside Russia it is encountered chiefly as a research chemical rather than a licensed medicine, and it holds no approval from the United States Food and Drug Administration or the European Medicines Agency.
The peptide is a synthetic analogue of epithalamin, a preparation extracted from bovine pineal glands. Investigators sought a short, chemically defined molecule that would reproduce some of the endocrine and gerontological observations attributed to the glandular extract. Proposed mechanisms centre on induction of telomerase activity, an effect reported in cultured human somatic cells in the early 2000s, together with influences on melatonin secretion and neuroendocrine regulation. Those mechanisms remain incompletely characterised, and the reported telomerase response has not been consistently reproduced by independent groups working in comparable systems.
| Property | Value | Notes |
|---|---|---|
| Amino acid sequence | Ala-Glu-Asp-Gly | Linear tetrapeptide, also written AEDG |
| Molecular mass | About 390.35 g/mol | Value calculated from the sequence |
| Appearance | White to off-white powder | Lyophilised material forms a loose cake |
| Solubility | Freely soluble in water | Also dissolves in isotonic saline |
| Storage | -20 °C, desiccated | Aliquot solutions to avoid freeze–thaw cycling |
The compound is generally described as a synthetic analogue of a fragment isolated from a pineal gland extract. Researchers associated with the Saint Petersburg Institute of Bioregulation and Gerontology introduced it during the 1980s and 1990s while studying short peptides from animal tissue. The original extract, called epithalamin, is a heterogeneous mixture, whereas epitalon is a single defined sequence. That distinction matters because findings reported for the extract are not automatically findings about the pure tetrapeptide, and claims about broader biological effects remain a separate question from the chemical identity described here.
Residue composition is the property that most cleanly separates verified material from mislabelled samples. Alanine, glutamate, aspartate and glycine appear in that order from the N-terminus, and the two acidic residues sit in the middle of the chain. Because the peptide is short, it can be produced by solid-phase synthesis and characterised by mass spectrometry without ambiguity. Any reported sample whose measured mass departs substantially from 390 daltons is a different compound or a degraded mixture rather than epitalon.
Epitalon is a synthetic tetrapeptide whose sequence is alanine-glutamate-aspartate-glycine, written in single-letter code as AEDG. The four residues are joined by three peptide bonds, giving a linear backbone with no branching and no disulfide bridges. Its calculated molecular mass for the free form is approximately 390.3 daltons, a figure that rises when the compound is supplied as an acetate or trifluoroacetate salt. Because the chain is short, the molecule is defined entirely by its residue order rather than by any folded three-dimensional structure.
The compound is described in the literature as a derivative of epithalamin, a preparation obtained from bovine pineal tissue. Work on this peptide family was carried out mainly by a research group in Saint Petersburg beginning in the 1980s, and the substance was later registered for clinical use in Russia under the name Epitalon. Outside that region it is generally treated as a research chemical rather than an approved medicine. Statements about its biological activity rest on a relatively small number of studies, and independent replication remains limited.
Ion mobility spectrometry-mass spectrometry (IMS/MS or IMMS) is a technique where ions are first separated by drift time through some neutral gas under an applied electrical potential gradient before being introduced into a mass spectrometer. Drift time is a measure of the collisional cross section relative to the charge of the ion. The duty cycle of IMS (the time over which the experiment takes place) is longer than most mass spectrometric techniques, such that the mass spectrometer can sample along the course of the IMS separation. This produces data about the IMS separation and the mass-to-charge ratio of the ions in a manner similar to LC-MS. The duty cycle of IMS is short relative to liquid chromatography or gas chromatography separations and can thus be coupled to such techniques, producing triple modalities such as LC/IMS/MS.
== Function == SLC15A1is localized to the brush border membrane of the intestinal epithelium and mediates the uptake of di- and tripeptides from the lumen into the enterocytes. This protein plays an important role in the uptake and digestion of dietary proteins. This protein also facilitates the absorption of numerous peptidomimetic drugs. Peptide transporter 1 functions in nutrient and drug transport have been studied using intestinal organoids.
Art and culture became strictly regulated under the principles of socialist realism and Russian traditions that Stalin admired were allowed to continue. Foreign policy in the Soviet Union from 1929 to 1941 resulted in substantial changes in the Soviet Union's approach to its foreign policy. In 1933, the Marxist–Leninist geopolitical perspective was that the Soviet Union was surrounded by capitalist and anti-communist enemies. As a result, the election of Adolf Hitler and his Nazi Party government in Germany initially caused the Soviet Union to sever diplomatic relations that had been established in the 1920s. In 1938, Stalin accommodated the Nazis and the anti-communist West by not defending Czechoslovakia, allowing Hitler's threat of pre-emptive war for the Sudetenland to annex the land and "rescue the oppressed German peoples" living in Czecho. To challenge Nazi Germany's bid for European empire and hegemony, Stalin promoted anti-fascist front organisations to encourage European socialists and democrats to join the Soviet communists to fight throughout Nazi-occupied Europe, creating agreements with France to challenge Germany. After Germany and Britain signed the Munich Agreement (29 September 1938) which allowed the German occupation of Czechoslovakia (1938–1945), Stalin adopted pro-German policies for the Soviet Union's dealings with Nazi Germany.
=== Vertical farming === Some benefits of vertical farming include that plants grown with this technique can take place inside, be stacked up in layers, and can take advantage of soilless plant-growing techniques such as hydroponics.
=== Gene therapy === Gene therapy to overcome the genetic mutations that cause MSUD appears in preliminary trials [1] to be safe in animal studies with MSUD. The gene therapy involves a healthy copy of the gene causing MSUD being produced and inserted into a viral vector. The adeno-associated virus vector is delivered one time to the patient intravenously. Hepatocytes will take up vector and functional copies of the affected gene in MSUD patients will be expressed. This will allow BCAA to be broken down properly and prevent toxic build-up.
Sources: en.wikipedia.org
Pratītyasamutpāda (Sanskrit: प्रतीत्यसमुत्पाद, Pāli: paṭiccasamuppāda), commonly translated as dependent origination, or dependent arising, is a key doctrine in Buddhism shared by all schools of Buddhism. It states that all conditioned dharmas (phenomena) arise in dependence upon other dharmas: "if this exists, that exists; if this ceases to exist, that also ceases to exist". The basic principle is that all conditioned things (saṅkhata dharmas, conditioned phenomena, conditioned principles) arise in dependence upon other things. The doctrine includes depictions of the arising of suffering (anuloma-paṭiccasamuppāda, "with the grain", forward conditionality) and depictions of how the chain can be reversed (paṭiloma-paṭiccasamuppāda, "against the grain", reverse conditionality). These processes are expressed in various lists of dependently originated phenomena, the most well-known of which is the twelve links or nidānas (Pāli: dvādasanidānāni, Sanskrit: dvādaśanidānāni). The traditional interpretation of these lists is that they describe the process of a sentient being's rebirth in saṃsāra, and the resultant duḥkha (suffering, pain, unsatisfactoriness), and they provide an analysis of rebirth and suffering that avoids positing an atman (unchanging self or eternal soul). The reversal of the causal chain is explained as leading to the cessation of rebirth (and thus, the cessation of suffering). Another interpretation regards the lists as describing the arising of mental processes and the resultant notion of "I" and "mine" that leads to grasping and suffering.
Ro 28-2653 is highly selective for MMP-2, MMP-9 and membrane type 1 (MT-1)-MMP. It is an antitumor and antiangiogenic agent with oral bioavailability. Inhibition of TACE and MMP-1 are linked to the musculoskeletal side effects seen in hydroxamate metalloproteinase inhibitors, but this compound spares the enzymes. It has been shown to diminish tumor growth in nasal cancer in rats as well as prostate cancer cell cultures. The compound only has moderate effect on mice's adipose tissue and no alteration on joints. Based on this, it is concluded that class of inhibitors is less likely to trigger neuromuscular adverse effects. On the active site of the structure is a pyrimidinetrione chelation and the phenyl and piperidynil section occupy the S1’ and S2’ binding pockets of MMP-8. Compound 556052-30-3 is similar to Ro 28-2653 but incorporates a 4-((2-methylquinolin-4-yl)methoxy)phenyl sidechain that is TACE selective. 5-(spiropyrrolidin-5-yl)pyrimidinetrione is a compound named 848773-43-3 that is a potent MMP-2, MMP-9 and MMP-13 inhibitor that spares MMP-1 and TACE. By substituting 1,3,4-oxadiazol-2-yl heteroaryl at C-4’ of the diphenylether segment to accomplish MMP-13 selectivity over MT-1 MMP, made the compound 420121-84-2. The compound has IC50 (half maximal inhibitory concentration) of 1 nM for MMP-13. I125-radioable pyrimidinetriones that have similar structure have been made to be used in MMP-9 elevated atherosclerosis and elevated MMP-2 and MMP-9 cancers. This class of MMP inhibitors is easy to synthesize and are potent enough for clinical valuation.
== Death and legacy == In late 1842, Jardine's health had rapidly deteriorated due to colon cancer. In the latter part of the year, Jardine was already bedridden and in great pain. He was assisted by his nephew, Andrew Johnstone and later on by James Matheson in his correspondence. Despite his illness, Jardine was still very active in keeping an eye on business, politics and current affairs, and continued to welcome a steady stream of visits from family members, business partners, political associates and his constituents. He died on 27 February 1843, just three days after his 59th birthday, one of the richest and most powerful men in Britain and Member of Parliament. Jardine's funeral was attended by a very large gathering of family, friends, government and business personalities, many of whom Jardine had helped in his lifetime. Jardine, a bachelor, willed his estate to his siblings and his nephews. Though gleaning from Oxford University Press' immense collection of Jardine Matheson's correspondence from its earliest years, it can be speculated that Jardine had an illegitimate child, a daughter, with a 'Mrs. Ratcliffe' who was provided with an annual pension and shares with Jardine's firms which was later on cashed out years after Jardine's death. Jardine had provided extensive correspondence with various associates in London instructing to carry out provisions to Mrs. Ratcliffe and her daughter, named Matilda Jane or 'Tilly' as Jardine affectionately called her in his letters. There were also letters from Tilly to Jardine requesting for additional monetary assistance.
Although rubidium is more abundant in Earth's crust than caesium, the limited applications and the lack of a mineral rich in rubidium limits the production of rubidium compounds to 2 to 4 tonnes per year. Several methods are available for separating potassium, rubidium, and caesium. The fractional crystallization of a rubidium and caesium alum (Cs,Rb)Al(SO4)2·12H2O yields after 30 subsequent steps pure rubidium alum. Two other methods are reported, the chlorostannate process and the ferrocyanide process. For several years in the 1950s and 1960s, a by-product of potassium production called Alkarb was a main source for rubidium. Alkarb contained 21% rubidium, with the rest being potassium and a small amount of caesium. Today the largest producers of caesium produce rubidium as a by-product from pollucite.
Sources: en.wikipedia.org
It is a synthetic tetrapeptide. Its sequence was derived from research on peptide fractions of bovine pineal extract, and the intact AEDG sequence has not been demonstrated as an abundant free peptide in human tissue.
AEDG is the one-letter code for the four amino acids alanine, glutamate, aspartate and glycine in that order. The same molecule is written in three-letter form as Ala-Glu-Asp-Gly.
Identity is normally confirmed by mass spectrometry against the calculated mass of roughly 390.35 g/mol. Purity is then estimated by reversed-phase high-performance liquid chromatography with ultraviolet detection.
Epitalon is a synthetic four-amino-acid peptide with the sequence alanine–glutamate–aspartate–glycine, also written AEDG. It was developed in Russian gerontology research and is studied for proposed effects on telomerase, melatonin regulation, and neuroendocrine function. It is not an approved pharmaceutical in the United States or the European Union.